Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-11-01 | Apellis Pharmaceuticals, Inc. | Francois Cedric
(Chief Executive Officer) |
J | Common Stock | D | 182146 | $0.00 - $0.00 | $0 |
| 2024-09-27 | Apellis Pharmaceuticals, Inc. | Watson David O.
(General Counsel) |
G | Common Stock | D | 21138 | $0.00 - $0.00 | $0 |
| 2024-09-23 | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair
(Director) |
M | Common Stock | A | 4600 | $13.19 - $13.19 | $60,674 |
| 2024-09-16 | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair
(Director) |
S | Common Stock | D | 37000 | $36.09 - $36.79 | $1,340,595 |
| 2024-09-16 | Apellis Pharmaceuticals, Inc. | Chopas James George
(VP/Chief Accounting Officer) |
S | Common Stock | D | 192 | $36.21 - $36.21 | $6,951 |
| 2024-06-21 | Apellis Pharmaceuticals, Inc. | Dunlop A. Sinclair
(Director) |
S | Common Stock | D | 37000 | $39.22 - $39.63 | $1,451,834 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |